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Abstract
Hypoplastic left heart syndrome (HLHS) is among the most severe forms of congenital heart disease. Although the consensus
view is that reduced flow through the left heart during development is a key factor in the development of the condition, the
molecular mechanisms leading to hypoplasia of left heart structures are unknown. We have generated induced pluripotent
stem cells (iPSC) from five HLHS patients and two unaffected controls, differentiated these to cardiomyocytes and identified
reproducible in vitro cellular and functional correlates of the HLHS phenotype. Our data indicate that HLHS-iPSC have a re-
duced ability to give rise to mesodermal, cardiac progenitors and mature cardiomyocytes and an enhanced ability to differen-
tiate to smooth muscle cells. HLHS-iPSC-derived cardiomyocytes are characterised by a lower beating rate, disorganised sar-
comeres and sarcoplasmic reticulum and a blunted response to isoprenaline. Whole exome sequencing of HLHS fibroblasts
identified deleterious variants in NOTCH receptors and other genes involved in the NOTCH signalling pathway. Our data indi-
cate that the expression of NOTCH receptors was significantly downregulated in HLHS-iPSC-derived cardiomyocytes
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alongside NOTCH target genes confirming downregulation of NOTCH signalling activity. Activation of NOTCH signalling via
addition of Jagged peptide ligand during the differentiation of HLHS-iPSC restored their cardiomyocyte differentiation capac-
ity and beating rate and suppressed the smooth muscle cell formation. Together, our data provide firm evidence for involve-
ment of NOTCH signalling in HLHS pathogenesis, reveal novel genetic insights important for HLHS pathology and shed new
insights into the role of this pathway during human cardiac development.
Introduction
Hypoplastic left heart syndrome (HLHS) is a severe combina-
tion of congenital cardiac malformations characterised by un-
der development of the left-sided cardiac structures, including
hypoplasia of the left ventricle, stenosis or atresia of the aortic
and mitral valves and hypoplasia of the ascending aorta and
aortic arch, resulting in a circulatory system reliant on the
right ventricle only (1). HLHS occurs in 0.03% of neonates and
is fatal without immediate post-partum palliative surgery (2).
Prognosis is generally poor with many patients requiring a
heart transplant due to congestive cardiac failure. The use of
allogeneic stem cell transplantation as a therapy for HLHS has
been studied in several clinical trials, but found to produce
only modest improvements in left ventricular function (3–5).
A more detailed understanding of the pathogenesis of HLHS is
needed in order for effective treatments to be developed. A greater
understanding of genetic and/or epigenetic contributions to the
disease during embryonic development is central to this need.
There is a substantial familial predisposition to HLHS (6) but
the genetic determinants of the disease are largely unknown. The
aetiology of HLHS is thought to be multifactorial, attributed to a
combination of complex inheritance and environmental influ-
ences (7). There is evidence from the literature that HLHS may re-
sult from embryonic abnormalities of blood flow (8,9) especially
since the most severe presentations of the disease occur in those
patients with mitral and aortic atresia. However since not all neo-
nates born with HLHS suffer from valvular or outflow tract mal-
formation (8), it has been hypothesised that dysfunction of
genetic networks specific to the left ventricular chamber and out-
flow tract are also contributory to the pathogenesis of the condi-
tion. In support of this notion, it has been shown that loss-of-
function mutations in the gene HAND1 (which is expressed in
left-sided cardiac structures including the left ventricular myo-
cardium) is associated with HLHS (10). HAND1 participates in a
core transcriptional regulatory network coupled to NKX2.5 and
NOTCH1 (11–13). NOTCH1 has been linked to HLHS owing to its
contribution to a Mendelian form of calcific aortic valve disease
(12,14–16) and the identification of pathogenic compound hetero-
zygous NOTCH1 mutations in HLHS patients (15,17). A variety of
other gene mutations or differential expressions have been iden-
tified to be associated with HLHS, including cardiac transcription
factors NKX2.5 (18), TBX5 (19), ETS1 (20), FOXC1/FOXC2 (21,22), cell
adhesion molecule PECAM-1 (23) and cardiac gap junction protein
GJA1 (24). However, any myocardial susceptibility component is
as yet undefined. Chromosomal disorders are also reported to be
associated with HLHS. 10% of all infants born with a terminal 11q
deletion (Jacobsen syndrome) have HLHS (25). Hinton et al. re-
ported that HLHS links to chromosome regions 10q22 and 6q23
and is genetically related to bicuspid aortic valve (BAV) (26). The
observation that bicuspid aortic valve (BAV) is more common in
pedigrees containing a HLHS proband than in the general popula-
tion has led to the suggestion that HLHS is a severe form of valvu-
lar malformation; however the extreme discrepancy between the
incidence rates of BAV and HLHS argues against the idea that
BAV is a major cause of HLHS. Although families with a case of
HLHS frequently also have cases of BAV, very few families contain-
ing a case of BAV also contain a case of HLHS. This could be ex-
plained by the co-occurrence of a genetic predisposition to a mild
and/or embryologically transient left-sided obstructive lesion
(which could be caused by relatively common alleles, given the
prevalence of bicuspid aortic valve in the population) and a rare -
and possibly de novo - genetic predisposition to reduced myocardial
growth in the presence of mildly or transiently reduced flow. This
could produce the HLHS phenotype in family members with both
genetic predisposing factors, whilst other family members without
the ‘second hit’ impacting myocardial development would mani-
fest only the residuum of the transient obstruction (BAV).
The rarity of HLHS renders large-scale genetic epidemiological
studies unfeasible (most investigations in the literature involve less
than 40 HLHS probands). Gene expression studies of human samples
attempting to identify causative pathways have been restricted to
the study of the right ventricle (since the left ventricle does not de-
velop in HLHS) in postnatal life (27). It is therefore unclear whether
the expression differences that have been described between HLHS
and normal hearts are relevant to left ventricle chamber under de-
velopment, or merely the consequence of right ventricle overload
during development. In this context, we believe the use of induced
pluripotent stem cell (iPSC) technology is a particularly appropriate
approach to disease modelling which enables the study of earliest
stages of embryonic cardiac development in patient specific cardio-
myocytes. Indeed, our group and few others have performed model-
ling studies in iPSC-derived cardiomyocytes from HLHS patients,
and have shown that HLHS iPSC have a reduced ability to differenti-
ate into cardiomyocytes (12,17,28) and that these show a multitude
of molecular and functional deficiencies when compared to equiva-
lent cells derived from unaffected controls. The study of Gaber et al.
(29) is interesting in that it implicates both TGFb signalling and pre-
mature senescence of cardiomyocyte progenitor cells. Another study
implicates transcriptional repression of NKX2-5, HAND1, and
NOTCH1 (12), thus it is plausible that multiple gene or signalling
pathway dysfunctions may contribute to HLHS.
To investigate whether common genetic dysfunctions con-
tribute to HLHS, we isolated iPSC from five HLHS patients and
age matched unaffected controls and differentiated these to
cardiomyocytes. Using a combination of cellular and molecu-
lar assays and next generation sequencing, we were able to
identify reproducible in vitro cellular and functional correlates
of the HLHS phenotype and we identified deleterious variants in
the NOTCH signalling pathway in all HLHS patients. Reactivation
of the NOTCH signalling pathway resulted in reversal of cellular
phenotypes and generation of cardiomyocytes that were indistin-
guishable of those obtained from unaffected individuals, placing
this pathway at the heart of HLHS aetiology.
Results
Derivation and characterisation of control and HLHS-
patient specific iPSC lines
We reported the development of an in vitro model of HLHS based
upon the differentiation of one HLHS patient specific iPSC (named
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HLHS) to cardiomyocytes in a previous publication (28). In the
current study, we extended the validity of this approach by deriv-
ing iPSC lines from a further four neonatal HLHS patients re-
cruited at the Newcastle Freeman Hospital (HLHS1, 2, 3 and 6)
and two unaffected controls whose dermal skin fibroblast sam-
ples were obtained from Lonza (Table 1). All iPSC clones were de-
rived from reprogramming of dermal fibroblasts using the RNA
based non-integrative Sendai virus (Thermo Fisher Cytotune 2
Kit). Since the initial control and HLHS-iPSC line was generated
using a lentiviral based approach, we derived new iPSC clones
from this patient fibroblasts using the Sendai virus approach. The
HLHS patient specific iPSC and control iPSC lines derived from
unaffected individuals showed all the hallmarks of pluripotent
phenotype (Fig. 1A–C), were genetically identical to parent fibro-
blasts (Supplementary Material, Fig. S1B) and capable of multili-
neage differentiation both in vitro and in vivo (Fig. 1D and E).
Several regions of loss of heterozygosity in chromosomes 3, 16
and 19 were observed in some HLHS patient fibroblasts and re-
sulting iPSC clones (Supplementary Material, Fig. S1A) and given
that they are shared between several unrelated HLHS patients,
they may bear some relevance for the causes of HLHS, however
this remains to be investigated further.
Differentiation of HLHS patient-specific iPSC reveals
cardiomyocyte cellular, structural and functional
abnormalities
HLHS patient-specific and control iPSC lines were differentiated
into cardiomyocytes (Fig. 2A and B) using the embryoid body
(EB) based protocol published by Keller’s group which enables
stepwise specification of mesoderm, cardiac progenitors and
cardiomyocytes (30). For all patients and controls, two iPSC
clones (to account for clonal variability) were differentiated into
cardiomyocytes; hence all data presented in this manuscript
are the average obtained from experiments conducted as bio-
logical triplicates from both clones of each HLHS patient (n¼ 6)
and two unaffected controls (n¼ 12). The disease-specific iPSC
lines exhibited a reduced capacity to generate spontaneously
contracting cardiomyocyte clusters (Fig. 3A) and within these,
the beating rate was significantly reduced (Fig. 3A), corroborat-
ing our previous findings (28). These observations may imply
functional defects in cardiomyocytes derived from HLHS-iPSC.
Our flow cytometric analysis also indicated a significant dif-
ference in the ability of HLHS-iPSC to differentiate towards cells
of a cardiac lineage. We observed a significant reduction in the
percentage of cells expressing the mesodermal marker
(BRACHYURY) and cardiomyocyte progenitor markers (ISL1,
NKX2.5) at day 7 of the differentiation time course (Fig. 3B).
Equally, a reduced percentage of cells expressed HAND1 and
HAND2 by day 14 (Fig. 3C) as well as cardiomyocyte specific
markers cTnT and SIRPA (31) was noted at both days 14 (Fig. 3C)
and 21 of differentiation (Supplementary Material, Fig. S2). This
reduced percentage of cells expressing cardiac progenitor and
cardiomyocyte markers was observed at later differentiation
time points (up to day 50), indicating that this phenomenon is
not due to a delayed differentiation and suggests an impaired
ability of HLHS-iPSC to undergo cardiac differentiation. As re-
ported by Kattman et al. (30), no endothelial cells (identified by
CD31 expression) were generated in either control or HLHS cul-
tures following the EB differentiation protocol, suggesting that
the generation of this cell type is not supported by the current
culture conditions. In contrast, the percentage of cells express-
ing the smooth muscle marker (a-SMA) was significantly
increased at both days 14 and 21 despite no change in expres-
sion of the fibroblast marker (Thy1) which typically marks the
cardiac fibroblasts, suggesting a preference for smooth muscle
differentiation over cardiomyocytes during HLHS-iPSC differen-
tiation (Fig. 3C). These data were further corroborated by in-
creased expression of the smooth muscle marker genes,
CALDESMON, CALPONIN and SMA22A (Supplementary Material,
Fig. S3). A recent report by Gaber et al. has highlighted activation
of TGFb signalling in HLHS foetal hearts, leading to epithelial
mesenchymal transformation of cardiac fibroblasts to myofibro-
blasts that are characterized by some features of smooth mus-
cle differentiation and typically express a-SMA. Gaber et al. went
to suggest that these proliferating myofibroblast contribute to
cardiac fibrosis which leads to stiffening of the ventricular
walls, diminished contractility, and abnormalities in cardiac
conductance (32). Despite observing increased expression of
TGFb1 in HLHS derived cardiomyocytes, we were unable to find
increased expression of TGFb target genes (GDF3, NODAL; data
not shown); therefore we are inclined to speculate that in-
creased expression of smooth muscle markers during differenti-
ation of HLHS-iPSC to cardiac lineages most likely reflects an
altered differentiation fate during iPSC differentiation.
We analysed ultrastructural and functional characteristics
of HLHS-specific cardiomyocytes in greater detail using trans-
mission electron microscopy (TEM). Control iPSC- derived cardi-
omyocytes show well organised myofibrillar bundles with
transverse Z bands (Fig. 4A–C), whereas those apparent in
HLHS-iPSC-derived cardiomyocytes are less organised with
poorly defined Z bands present at irregular spacing (Fig. 4D–R).
In our previous publication, we studied the response of HLHS-
iPSC-derived cardiomyocytes to the b1/b2 adrenergic receptor
agonist isoprenaline, which normally increases the contraction
frequency by enhancing Ca2þ ATPase activity in the sarcoplas-
mic reticulum (28). In this work we studied the same parameter
in iPSC-CMs from two additional HLHS and one unaffected con-
trol iPSC line. Given the emergence of cells that express smooth
muscle markers in during differentiation HLHS-iPSC but not
control lines with the Kattman method (31), to obtain purified
cultures of cardiomyocytes for electrophysiological characteri-
sation, all iPSC lines were differentiated using a monolayer dif-
ferentiation protocol that results in a high efficiency of
cardiomyocyte generation (> 85% cTnTþ, please refer to meth-
ods). The frequency of calcium transients increased in response
to isoprenaline exposure in all cell lines; however the magni-
tude of this increase was significantly reduced in the HLHS lines
compared to the control line (Supplementary Material, Fig. S4),
corroborating our previous findings (28).
Furthermore, we performed RNA-seq analysis of cardiomyo-
cytes generated from one of the HLHS patients and one unaf-
fected control and following bioinformatic analysis we identified
163 significantly downregulated genes (corrected p value  0.05
and fold change  2.0) (Supplementary Material, Table S1).
Amongst the downregulated genes were two cardiac sarcomeric
proteins: (1) a ventricular isoform of myosin heavy chain (MYH7B)
specifically expressed in heart and linked with hypertrophic car-
diomyopathy and left ventricular non-compaction and (2)
Troponin I 3 (TNNI3) expressed exclusively in cardiac muscle and
already linked with both dilated cardiomyopathy and familial re-
strictive cardiomyopathy. The reduced expression of these two
key genes supports the notion that cardiomyocyte differentiation
is less efficient from HLHS-iPSC than controls. A large number of
protocadherins and cadherins, encoding essential members of
membrane-associated glycoproteins which are critical for cell to
cell communication and regulators of intra-cellular calcium
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Figure 1. Characterization of HLHS patient specific iPSC lines. (A) Brightfield images of two clones derived from each patient using the non-integrative RNA based
Sendai virus; (B) Representative example of flow cytometric analysis of key pluripotent cell markers, TRA-1-60 and NANOG. A representative example is shown from
HLHS1 clone 1, however similar results were obtained for all HLHS and unaffected iPSC lines; (C) Elimination of Sendai viral vectors from derived iPSC lines (KOS stands
for KLF4, OCT4 and SOX2); (D) Immunofluorescent images showing antibody staining of cells derived from all three germ layers: neuronal class b-III-tubulin staining
neuronal cells derived from ectoderm; a-Smooth muscle actin staining smooth muscle cells derived from mesoderm aFP (alpha-fetoprotein) staining endodermal cells.
A representative example is shown from HLHS2 clone 1; however similar results were obtained for all HLHS and unaffected iPSC lines. (E) In vivo differentiation of
HLHS1-clone 1 as a representative example of teratoma forming ability of HLHS patient specific iPSC lines. (A) low power showing heterogeneous structure of the tera-
toma; (B) neuroepithelium; (C) cartilage; (D) intestinal epithelium. (A: scale bar¼ 400 mm, B-D: scale bar¼50 mm).
Table 1. Summary of the HLHS patients and iPSC lines derived therefrom and the unaffected controls
Name Cell Source Clinical Manifestation Sex
HLHS Neonatal fibroblasts- Coriell
Institute for Medical
Research: GM12601
Aortic and mitral atresia. Associated
malformations included mild facial
dysmorphism, bilateral hip dislocation,
hypoplastic fingernails and mild
microcephaly
Male
HLHSI Neonatal fibroblasts Mitral and aortic atresia,
intact inner atrial septum
Male
HLHS2 Neonatal fibroblasts Mitral and aortic atresia Female
HLHS3 Neonatal fibroblasts Mitral and aortic atresia Male
HLHS6 Neonatal fibroblasts Mitral and aortic atresia Female
Control SB -Neol Neonatal fibroblasts (Lonza) Normal individual Male
Control SB-Ne03 Neonatal fibroblasts (Lonza) Normal individual Male
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concentration were also included in this category
(Supplementary Material, Table S1). Genes encoding two essential
proteins, calsequestrin (CASQ2) and histidine rich calcium-bind-
ing protein (HRC) located in the sarcoplasmic reticulum and play-
ing key roles in calcium homeostasis in cardiomyocytes were
downregulated, suggesting an impaired sarcoplasmic reticulum
function in HLHS cardiomyocytes. GO Biological and Molecular
function as well as phenotypic searches performed using the
Gene Analytics gene set analysis tool (https://ga.genecards.org/)
indicated a range of processes that were affected including myo-
cardial fibre morphology, sarcomere morphology, calcium ion
binding, cell adhesion, regulation of cardiac muscle contraction
by regulation of the release of sequestered calcium ion etc. which
corroborate the full range of phenotypic abnormalities reported
above. Since the RNA-seq experiment compared cardiomyocytes
derived from one HLHS patient and one control, we performed
additional qRT-PCR which confirmed downregulation of genes in-
volved in cell adhesion, muscle contraction, actin binding pro-
teins and myocardium fibre morphology (Supplementary
Material, Fig. S5) in all HLHS samples compared to unaffected
controls. Together, our data replicate the initial findings pub-
lished by our group (28) and show that the multiple molecular,
structural and functional differences are reproducible in vitro
characteristics of iPSC lines derived from patients with HLHS
compared to controls which implies that patient cardiomyocyte-
specific factors make a substantial contribution to the develop-
ment of HLHS.
Dysfunction of the NOTCH signalling pathway underlies
HLHS aetiology
Since the dysfunction of HLHS patient specific cardiomyocytes
seems to be conserved across a number of patients and develops
in vitro, independently of the growth of other structures that con-
tribute to the formation of the embryonic heart, a genetic contri-
bution to HLHS manifesting in cardiomyocytes seems more likely
and we therefore sought to identify genetic variants that could
predispose to HLHS. We performed whole exome sequencing on
the five HLHS patients using the Agilent SureSelect system exome
capture and sequencing protocol. Despite the small sample size
and lack of parental or sibling DNA (this preventing identification
of mode of inheritance), we sought to identify deleterious variants
that may elucidate potential and common mechanisms for the
cellular phenotypes described above. Deleterious in our study was
defined by at least one of the predictors [SIFT (32) or PolyPHEN2
(33)] and those that had alternative allele frequency less than 0.01
in both 1000 Genomes project and ESP6500 (Table 2). Over 200 del-
eterious variants were identified in each of the five HLHS patients.
Further selection of these variants was carried out using the
LifeMap Discovery Tools [VarElect, GeneCards, MalaCards (34,35)]
and PubMed using the search terms: cardiomyocytes, HLHS, mi-
tral stenosis, aortic stenosis, bicuspid valve, outflow tract prob-
lems, cardiac vasculogenesis, patent ductus arteriosus, congenital
heart disease, heart development, cardiomyocyte and smooth
muscle development and sarcomere assembly and function.
Figure 2. Differentiation of iPSC lines to cardiomyocytes. (A) Overview of the protocol used for differentiation of control and HLHS patient specific iPSC to cardiomyo-
cytes; (B) Representative immunocytochemical staining of cardiomyocytes derived from control and HLHS patient specific iPSC lines using antibodies raised against al-
pha actinin and cardiac troponin. One clone from each patient and unaffected control is shown; however similar data were obtained for the second clone. Scale
bar¼100 mm.
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An important final criterion for our analysis was communality of
deleterious variants between all HLHS patients. From this analy-
sis, we observed that three of the HLHS patients (HLHS3, HLHS6
and HLHS) harboured at least one deleterious variant in NOTCH
signaling receptors (NOTCH1, NOTCH3 and NOTCH4) genes (Table
3) despite these variants not being identical in each patient.
The remaining two patients (HLHS1 and HLHS2) harboured
variants in NOTCH receptor genes (NOTCH4 and NOTCH2),
although the later were not predicted to be deleterious from our
bioinformatic analysis. Furthermore, all HLHS patients harboured
deleterious variants in multiple genes involved in the NOTCH
signaling pathway (Table 3). In total 8 variants in NOTCH recep-
tors were found in HLHS fibroblast samples, four of which
were previously reported (11,36,37), with the remaining
four being novel (NOTCH3:exon11:c.A1766C:p.Q589P, NOTCH4:
exon1:c.33_44del:p.11_15del, NOTCH4:exon1:c.17_28del:p.6_10del
Figure 3. HLHS iPSC lines show an impaired ability to give rise to cardiomyocytes. (A) Analysis of the percentage and beating frequency of EBs that generate contraction
during differentiation of control and HLHS patient specific iPSC. At least 100 EBs were assessed for each biological replicate; (B) Flow cytometry data analysis demon-
strating a lower ability of HLHS-iPSC lines to give rise to mesodermal and cardiac progenitors when compared to control derived cells at day 7 of the differentiation
time-course; (C) Flow cytometry data analysis demonstrating that HLHS-iPSC lines have a lower ability to give rise to cardiomyocytes but have an enhanced ability to
differentiate to smooth muscle cells when compared to control derived cells at day 14 of the differentiation time-course. One way Anova analysis with Dunnett multi-
ple comparison tests was performed. ***P<0.001; **P value between 0.001 and 0.01; *P value between 0.01 and 0.05.HLHS iPSC lines: N¼6 (2 clones triplicate biological
repeats); control iPSC lines: N¼12 (2 clones triplicate biological repeats2 unaffected control iPSC lines).
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and NOTCH4:exon18:c.G2834A:p.C945Y (Fig. 5A). The presence of
all 8 variants was confirmed by direct sequencing (Fig. 5B). These
variant loci span a wide range in NOTCH receptor gene open read-
ing frames involving signal peptide, EGF-like repeat domains,
transmembrane region and transcriptional activation domain
which might interrupt NOTCH trafficking, receptor activation, pro-
teolytic cleavage cascade and transcriptional activating functions.
Together, these data suggest that mutations in key components
of the NOTCH signalling pathway leading to dysfunction of this
important pathway may underline the HLHS aetiology.
To validate the dysfunction of NOTCH signalling pathway in
HLHS-iPSC-derived cardiomyocytes, we performed quantitative
RT-PCR analysis which indicated a significant downregulation
in the expression of NOTCH1-4 receptors and NOTCH targets
(DTX1, FOS, HEY2 and HEYL), thus confirming the impairment of
NOTCH signaling pathway in HLHS-iPSC-derived cardiomyo-
cytes (Fig. 6). It is of interest to note that we also observed down-
regulation of NOTCH-binding proteins (JAG1 and JAG2) which
may reflect an autocrine feedback loop in NOTCH signalling
pathway. Downregulation of several NOTCH targets and NOTCH
binding proteins including HEY2 and JAG2 was also confirmed
by the RNA-seq analysis described in previous results section
(data not shown). To further assess the role of dysfunctional
NOTCH signalling on the aetiology of HLHS, we performed
HLHS-iPSC differentiation to cardiomyocytes in the presence of
a Notch ligand (Jagged peptide) or Scrambled control as de-
scribed by Arumugam et al. (38). The addition of Jagged peptide
was carried out in HLHS1 patient which has two NOTCH4 muta-
tions in the protein signal peptide domain (Fig. 5 and Table 3).
Mutations in the signal peptide domain are thought to affect
the cytoplasmic expression of Notch proteins and inhibition of
proteasome activity, thus impacting on NOTCH protein process-
ing and function (39). However, such mutations are unlikely to
affect Jagged binding to Notch4 and activation of Notch path-
way in cardiomyocytes derived from this patient. Furthermore
the other Notch ligands (NOTCH1, NOTCH2 and NOTCH3) can
also be activated by Jagged 1 addition, thus resulting in an over-
all increase in the activity of NOTCH signalling which can res-
cue the impact of NOTCH4 mutation in these cells. Activation of
Notch signalling was confirmed by increased expression of
Notch targets such as DTX1, FOS, HEY1, HEY2 and HES1
(Supplementary Material, Fig. S6). This led to a significant in-
crease in capacity to generate cardiomyocyte clusters and beat-
ing rate (Fig. 7A and B) as well as increased percentage of cells
expressing HAND1 and HAND2 by day 14 (Fig. 7C) as well as car-
diomyocyte specific markers cTnT and SIRPA at both days
14 (Fig. 7C) and 21 of differentiation (data not shown).
Furthermore, the percentage of cells expressing the smooth
muscle markers (a-SMA) was significantly decreased at both
days 14 (Fig. 7C) and 21 (data not shown), suggesting a restora-
tion of cardiomyocyte differentiation capacity in HLHS-iPSC
lines. Together, these data indicate that dysfunction of NOTCH
signalling pathway is at the core of HLHS aetiology.
Discussion
In this current study, we have highlighted dysfunctional Notch
signalling in the aetiology of HLHS. In a previous publication,
we reported the successful derivation of iPSC from a single
HLHS patient and differentiation towards cardiomyocytes (28).
Although we were able to show a range of cellular, functional
and structural deficiencies in HLHS derived cardiomyocytes, it
was unclear whether these were common features underlined
the HLHS aetiology. In this present study, we report the deriva-
tion of iPSC lines from an additional four HLHS patients and
provide evidence that HLHS-iPSC-derived cardiomyocytes are
Figure 4. (A–C) Transmission electron microscopy ultrastructure of cardiomyocytes derived from an age matched control iPSC line (SB-Neo3) shows abundant myofi-
brillar bundles, regular transverse Z bands with intervals of around 2 mm (black arrows) and large amount of mitochondria (labeled ‘m’) similar to those observed in fe-
tal or neonatal cardiomyocytes. (D-R) A more random arrangement of myofibrils with poorly defined Z bands (black arrows) was observed in HLHS-iPSC-derived
cardiomyocytes. The interval between individual Z bands is frequently irregular and smaller (0.5–1.0 mm). Compared with control iPSC-CMs, HLHS-iPSC derivatives had
less mitochondria (labeled ‘m’) of smaller size and mal-formed inner membrane. One clone from each HLHS patient is shown; however similar data were obtained
from the second clone.
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characterised by the following common deficiencies: (1) reduced
beating rate, (2) disorganised sarcomere structure and (3) sarco-
plasmic reticulum dysfunction, all of which are reflected at the
gene expression level as revealed by RNA-seq analysis. These
data replicate the initial findings published by our group (28)
and show that the multiple expression, structural and func-
tional differences are reproducible in vitro characteristics of iPSC
lines derived from patients with HLHS compared to controls
which implies that patient cardiomyocyte-specific factors make
a substantial contribution to the development of HLHS. Our
data also indicate that cardiomyocyte specific defects are not an
isolated event and are associated with deficiencies observed
during the iPSC differentiation process which include a signifi-
cant reduction in the ability of HLHS-iPSC to give rise to beating
Figure 5. All HLHS patients harbour deleterious variants in genes involved in the NOTCH signalling pathway. (A) Summary of NOTCH receptor variants identified in
HLHS patients. Published NOTCH variants associated with HLHS are shown in cyan, published variants associated with congenital heart disease are shown in green
and published variants not associated with heart disease are shown in red. Novel variants uncovered by our exome analysis and not reported to date are shown in
black font. (B) Confirmation of variants by direct sequencing in HLHS patient and unaffected controls (representative examples). These mutations were not present in
the controls or other HLHS samples.
Table 2. Summary of exome sequencing performed on dermal skin fibroblasts obtained from the HLHS patients. A filtering strategy was used
for each patient as follows:
1. Exonic variants were generated by removing Synonymous SNVs and non-exonic variants.
2. Rare exonic variants were generated by removing variants with alternative allele frequency in either 1000Genomes project/ESP6500/cg69/
inHouseExomes/InHouse GATK Exomes greater than 0.05.
3. Rare interested hits were generated if they had both 1000Genomes Freq <¼ 0.01 and ESP6500 Freq <¼ 0.01.
4. X linked variants were generated by removing variants that were not on chromosome X.
5. Homozygous variants were generated by removing variants that were not on autosomal chromosomes, compound heterozygotes and het-
erozygous variants.
6. Compound heterozygotes were generated by keeping genes with two or more rare variants.
7. Deleterious variants were generated by selecting variants that were predicted Deleterious by at least one of the predictors (SIFT or
PolypHEN2) and those that had alternative allele frequency less than 0.01 in both 1000Genomes project and ESP6500.
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cardiomyocyte clusters and reduced expression of mesodermal,
cardiac progenitors and cardiomyocytes markers reported by
our group and others previously (12,17,28). This reduced emer-
gence of cardiomyocytes was compensated for an increased
presence of cells expressing the typical smooth muscle markers,
which suggests an altered cell fate decision during early devel-
opment with respect to cardiomyocyte or smooth muscle for-
mation. Smooth muscle is very different from cardiac muscle in
many aspects including function, structure, contraction and
excitation-contraction coupling. It is possible that replacement
of cardiomyocytes with smooth muscle cells would contribute
to reduction of blood flow through the left ventricle which
seems to be a key factor for the development of HLHS in some
patients.
To date, increasing evidence supports a genetic basis for
HLHS and these include observations of familial clustering and
concurrence with specific chromosomal disorders (6,25) as well
as the presence of deleterious variants in genes such as
NOTCH1, NKX2.5, GJA1 and more recently MYH6 (40). The multi-
plicity of common cellular deficiencies observed during differ-
entiation of all HLHS-iPSC lines to cardiac lineages led us to
speculate that mutations in the same gene or genes playing a
role in a common pathway(s) may be responsible for HLHS phe-
notypes uncovered by the iPSC disease model. Our whole exome
sequencing analysis revealed the presence of deleterious vari-
ants in NOTCH receptor genes or other genes involved in the
NOTCH signalling pathway. Two out of the five HLHS patients
(HLHS3 and HLHS) harboured two and four variants in NOTCH1
and NOTCH4 genes, respectively; one patient (HLHS1) harboured
two different variants in NOTCH4 gene and the remaining two
patients (HLHS2 and HLHS6) harboured single variants in the
NOTCH2 and NOTCH3 genes. All patients also harboured delete-
rious variants on other genes implicated in NOTCH signalling
which led us to hypothesise that dysfunction of NOTCH signal-
ling was the key underlining mechanism for HLHS. While
NOTCH1 mutations have been linked with HLHS (12,17), the
presence of NOTCH2, NOTCH3 and NOTCH4 variants is novel and
not associated with the disease previously. We were unable to
Table 3. Summary of variants identified by exome sequencing analy-
sis in genes involved in the NOTCH signalling pathway. Deleterious
variants are shown in bold and compound heterozygotes have been
underlined
HLHS HLHS1 HLHS2 HLHS3 HLHS6
Exanic variants 35968 33891 35510 34651 35834
Rare exonic variants 2866 2610 2974 2659 2841
X-linked 42 19 82 24 74
Homozygous 125 108 127 121 140
Compound heterozygotes 514 517 711 524 579
Deleterious hits 281 238 272 265 288
Figure 6. Reduced expression of key components of NOTCH signalling pathway in HLHS iPSC lines. Quantitative RT-PCR analysis performed on day 14 iPSC- derived
cardiomyocytes showing decreased expression of NOTCH receptors, NOTCH ligands and targets in HLHS-iPSC-derived cardiomyocytes when compared to unaffected
controls. Data are presented as meanþ/- SEM. The values for fetal heart sample were set to 1 and all other values were normalised against this. One way Anova analy-
sis with Dunnett multiple comparison tests was performed. ****P<0.0001; ***P<0.001; ** P value between 0.001 and 0.01 *P value between 0.01 and 0.05. HLHS iPSC lines:
N¼6 (2 clones triplicate biological repeats), control iPSC lines: N¼12 (2 clones triplicate biological repeats2 unaffected control iPSC lines).
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collect DNA from the families of HLHS patients to assess
whether these were de novo or inherited changes. Nonetheless,
we were able to demonstrate that HLHS-iPSC-derived cardio-
myocytes had lower expression of all four NOTCH receptor and
target genes which indicates impaired NOTCH signalling activ-
ity in these cells. Most importantly, activation of NOTCH signal-
ling pathway via addition of Jagged ligand, resulted in reversal
of the key cellular and functional phenotypes (e.g. restoration of
beating rate, emergence of beating clusters, enhanced genera-
tion of cardiomyocytes and suppression of smooth muscle for-
mation) in HLHS-iPSC-derived cardiomyocytes which strongly
suggests that the dysfunction of the NOTCH signalling pathway
lies at the heart of the HLHS aetiology.
Notch signalling is an evolutionary conserved pathway with
important functions in many cellular events, including cellular
communication, maintenance of tissue boundaries, cell fate ac-
quisition, stem cell renewal and differentiation. Despite a
wealth of literature already published for Notch signalling, con-
tradictory reports exist on its role in differentiation of pluripo-
tent stem cells to cardiac lineages. Schroeder and colleagues
suggested that Notch signalling plays various roles during the
differentiation process and that its activation in murine models
results in suppression of mesodermal cell generation and their
further differentiation to cardiac muscle (41). Contrary to these
reported findings, a current report, suggests that biphasic Notch
regulation is needed for differentiation of murine embryonic
stem cells (mESC) and iPSC, since activation of Notch signalling
favours mesodermal induction at the early stages of differentia-
tion; however this is deleterious for formation of mature cardiac
progenitors at the later stages of differentiation (42). Activation
of Notch 1 or Notch 4 signalling in mESC derived haemangio-
blasts respecifies them to a cardiac fate (43), further adding to
the evidence that at least in the mouse pluripotent stem cell
model, Notch signalling plays different roles depending on the
temporal differentiation window and specific target cells.
In the human embryonic stem cell (hESC) system, it has
been reported that NOTCH inhibition promotes differentiation
of cardiac mesoderm, whilst NOTCH activation leads to an in-
crease in neural and smooth muscle cell markers (44,45); how-
ever, these studies did not apply a biphasic strategy of NOTCH
Figure 7. Activation of NOTCH signalling pathway restores the ability of HLHS- iPSC lines to give rise to cardiomyocytes. (A) Analysis of the percentage of EBs that gen-
erate contraction during differentiation of Jagged and scrambled peptide treated HLHS-iPSC line; (B) Analysis of beating frequency of EBs that generate contraction dur-
ing differentiation of Jagged and scrambled peptide treated HLHS-iPSC line; (C) Flow cytometry data analysis demonstrating that Jagged treatment enhances the ability
of HLHS-iPSC to give rise to cardiomyocytes and reduces the ability to differentiate to smooth muscle cells when compared to scrambled peptide treated control cells
at day 14 of the differentiation time-course. T-test analysis was carried out, ***P<0.001; **P value between 0.001 and 0.01; *P value between 0.01 and 0.05. Data are pre-
sented as meanþ/- SEM, n¼3þ.
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inhibition as in mouse, leaving open the question of whether
persistent or phase-specific NOTCH inhibition is beneficial to
hESC differentiation to cardiac lineages. However, in human cir-
culating progenitor cells, expression of a-sarcomeric actinin
and cTnT is associated with NOTCH signalling and is blocked by
preventing Notch signals with Y-secretase inhibitors (46), which
suggest that similarly to mouse cardiac progenitors, activation
of NOTCH signalling is essential for the acquisition of a cardiac
progenitor fate in humans. The HLHS-iPSC model we have de-
scribed herein provides an excellent model system from which
we can infer new insights on the role of Notch signalling during
iPSC differentiation. Our data suggest that a reduced NOTCH
signalling affects all stages of differentiation starting from com-
mitment to mesoderm, emergence of beating clusters, beating
rate and their further differentiation to cardiomyocytes.
Furthermore, a lower NOTCH signalling activity seems to shift
the differentiation balance from cardiomyocytes to smooth
muscle cells and such knowledge can be used to manipulate the
differentiation outcomes by manipulating NOTCH activity with
small molecule inhibitors or activators.
Currently, is not known, how Notch signalling may affect
the sarcoplasmic reticulum dysfunction observed in cardiomyo-
cytes derived from these HLHS patients. A recent report has
suggested that activation of Notch signaling by short term treat-
ment with Jagged-1 enhances store-operated calcium entry in
human pulmonary arterial smooth muscle cells in a dose de-
pendent manner (47). Hence it is possible, that activation of
Notch signalling may restore calcium homeostasis in HLHS-
iPSC-derived cardiomyocytes; however this needs to be investi-
gated further. It is also possible that mutations in genes other
than Notch receptors are responsible for the sarcoplasmic retic-
ulum dysfunction. For example, variants in Calcium Voltage-
Gated Channel Auxiliary Subunits (CACNB2, CACNA1I, CACNA1C
etc.) were identified in several of the HLHS patients included in
this study. The significance of these findings need to be vali-
dated by further molecular and functional studies and is cur-
rently ongoing in our group.
In summary, we have established a reliable model of HLHS
using the iPSC disease modelling approach and have revealed
consistent cellular and functional differences between unaf-
fected HLHS iPSC-derived cardiomyocytes which are under-
lined by likely mutations in genes involved in the NOTCH
signalling pathway. Although HLHS is an uncommon condi-
tion, and multiplex HLHS families are rare, investigation of the
biological mechanisms leading to HLHS could have wide im-
portance. Understanding cardiomyocyte growth and differen-
tiation has become a major research priority since the
development of hESC and iPSC technologies in the hope that
these might contribute to cardiac repair strategies. In this
manuscript, we have revealed an important role for a key sig-
nalling pathway (NOTCH) and its role during pluripotent stem
cell differentiation, thus providing important insights into
early human cardiomyocyte development and potential tools
and strategies for enhancing stem cell differentiation to de-
sired lineages (cardiomyocytes versus smooth muscle com-
mitment). Furthermore, our data have provided novel genetic
insights which can be taken forward for establishing molecu-
lar diagnosis tests for HLHS patients and genetic counselling
of affected families.
Last but not least, high throughput screening to identify ad-
ditional compounds that restore the genetic and functional pro-
file of HLHS cardiomyocytes to normal could result in novel
therapies, in the setting of in vitro growth promotion of cells for
cardiac regenerative medicine.
Materials and Methods
iPSC generation
Dermal fibroblasts were obtained from skin biopsies of all five
HLHS patients characterized by mitral and aortic atresia
(Table 1). iPSC derivation was performed using a CytoTuneVR -iPS
2.0 Sendai Reprogramming Kit (A16517) from Thermo Fisher
Scientific (Waltham, MA). In brief, fibroblasts were transduced
with the reprogramming vectors KOS (a polycistronic vector
encoding KLF4, OCT4, SOX2), hc-Myc and hKlf4 following manu-
facturer’s instructions. One week after transduction, fibroblasts
were disaggregated and plated onto feeder layers of mitotically
inactivated mouse embryonic fibroblasts in hESC culture me-
dium (KO-DMEM, 20% KnockoutTM Serum Replacement,
0.1 mMol nonessential amino acids, 2 mMol L-glutamine,
100 units/ml penicillin and 8ng/ml human recombinant bFGF,
all from Thermo Fisher Scientific) at a density of 8,000 cells per
well of a six well plate. The feeder plates with Sendai vector
treated cells were maintained at 37 C and 5% CO2 in hESC me-
dium for 2-3 weeks or until colonies with typical hESC morphol-
ogy appeared. Individual colonies were mechanically dissected
and plated onto Matrigel-coated plates (Corning, NY) using
mTeSR media (Stem Cell Technologies, Vancouver, British
Columbia, Canada) medium.
iPSC differentiation to cardiomyocytes
Differentiation of iPSCs towards cardiomyocytes was achieved
using a modified Keller protocol with StemPro-34 SFM medium
(Thermo Fisher Scientific) supplemented by growth factors (30).
iPSC colonies were dissociated and detached by enzymatic
treatment with 1mg/ml collagenase IV and 0.5 mg/ml Dispase
(Thermo Fisher Scientific) to form embryoid bodies (EBs) in sus-
pension culture with ultra-low attachment plates (Corning). A
summary of the cardiac differentiation protocol together with
concentrations and times of application of growth factors and
signalling molecules is shown in Figure 2A. BMP4, Activin A,
VEGF, DKK1 and SB431542 were purchased from R & D technolo-
gies (Minneapolis, MN), bFGF from Thermo Fisher Scientific,
Dorsomorphin from Sigma (St. Louis, MO) and Y27632 from
Chemdea (Ridgewood, NJ). At day 7, the EBs were seeded onto
Matrigel-coated plated and further cultured up to 30 days in
StemPro-34 SFM media supplemented with VEGF and bFGF. To
observe the effect of Notch signalling activation on cardiomyo-
cyte induction from iPSCs, 10 lM of Jagged (Jag-1 DSL peptide,
ANA61298, AnaSpec, Fremont, CA) was added into medium
from day 3 of differentiation. As control, 10 lM scrambled pep-
tide (ANA64239, AnaSpec, Fremont, CA) was applied in parallel.
At day 14 of differentiation, quantitative RT-PCR was carried out
to examine the gene expression levels of Notch ligands, recep-
tors and targets.
Immunocytochemistry
iPSC-derived cardiomyocytes were fixed in situ with 4% parafor-
maldehyde (PFA) fixative for 30 min. After 3 washes with PBS,
cells were permeabilised in 0.2% Triton X-100 for 30 min, blocked
for 1 h in 10% FCS and 1% BSA in phosphate buffer saline (PBS),
and incubated overnight at 4 C with primary antibodies diluted
1:200 in 1% BSA in PBS. The second day, the cells were washed
3 times with PBS and incubated with fluorescence-conjugated
secondary antibodies and DAPI in 1% BSA in PBS for 1 h at room
temperature. Images were taken by Eclipse Ti Confocal
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Microscope (Nikon, Minato-ku, Tokyo). The antibodies included
anti-b-III-tubulin (Thermo Fisher Scientific, A25532), anti-AFP
(Thermo Fisher Scientific, A25530), anti-SMA (Thermo Fisher
Scientific, A25531), anti-cTnT (Abcam, Cambridge, MA, Ab64623),
anti-a-Actinin (Thermo Fisher Scientific, MA1-22863).
Flow cytometric analysis
iPSCs and cardiomyocytes derived therefrom were dissociated
by incubation with Accutase (Thermo Fisher Scientific) for 5 min
at 37 C. A total of 1106 single cells were resuspended in PBS
supplemented with 5% fetal calf serum (FCS) and stained for the
presence of appropriate markers. For intracellular proteins,
staining was carried out on cells fixed with 4% paraformalde-
hyde for 10 min at 37 C and permeabilised with cold methanol
at -20 C. The primary antibodies included TRA-1-60 (1:200)
(Millipore, Ontario, Canada, FCMAB115F), NANOG (1:50) (Cell
Signaling Technology, Danvers, MA, 5448s), BRACHYURY (1:20)
(R&D, IC2085P), ISL1 (1:20) (Abcam, ab20670), NKX2.5 (1:100)
(R&D, MAB2444), cTnT (1:100) (Thermo, MS-295-P), SIRPA (1:20)
(Biogelend, 323808), HAND1 (1:50) (Abcam, Ab46822), HAND2
(1:50) (Abcam, Ab56590), aSMA (1:20) (Abcam, Ab32575), Thy1
(1:20) (BD, 559869), Connexin-43 (1:20) (Sigma, C 6219). At least
10,000 cells were analyzed for each experiment on an LSRII flow
cytometer and data were analyzed with FACSDiva software (BD
Biosciences, Franklin Lakes, NJ).
Teratoma formation in severe combined
immunodeficient mice
All procedures involving mice were carried out in accordance
with institutional guidelines and permission. Approximately
1106 iPS cells were injected subcutaneously into the right
flanks of adult NOD/SCID mice. All cells were co-transplanted
with 50ml Matrigel (BD Biosciences) to enhance teratoma forma-
tion. After 70–90 days, mice were sacrificed and teratoma tis-
sues were dissected. Material for histological analysis was fixed
in Bouins fixative [70% saturated picric acid (Sigma); 25% form-
aldehyde (37%/40%, Sigma); 5% glacial acetic acid (Sigma)] over-
night. Tissues were processed, sectioned to 6lm according
to standard procedures and counterstained with either
Haematoxylin and Eosin or Massons trichrome stain. Sections
were examined using bright field microscopy and photographed
as appropriate.
Exome sequencing
DNA was extracted from 5 HLHS patient fibroblasts using
QIAamp DNA Micro kit (Qiagen, Germantown, MD, 56304).
Exome sequencing was performed by BGI. Exome capture was
performed using Agilent SureSelect Human All Exon kit (V4).
Libraries were constructed following the Illumina Paired-End
Sequencing Library Preparation Protocol version 1.0.1 and then
sequenced on the Illumina GAIIx platform with version 4 chem-
istry and version 4 flowcells. The sequencing reads were ana-
lyzed using the following workflow to identify variants in
patient. The quality of sequencing reads was firstly checked
with FastQC (Version 0.11.2) (48). Low quality bases (Q< 20) on 3’
ends of reads were trimmed off using seqtk (Version 1.0) (49).
Duplicated reads were then removed with FastUniq (Version
1.1) (50) before mapping to the human reference genome
GRCh37 with BWA (Version 0.7.6.a) (49). The alignments were
refined with tools of the GATK suite (Version 3.2) (51). Variants
were called according to GATK Best Practice recommendations,
(52,53) including recalibration. Freebayes (Version 1.0.1) (54) was
also used to call variants from the same set of samples. The var-
iants called by Freebayes with total coverage 5, minor allele
coverage 5 and variants call quality 20 were added to those
identified by GATK. Non-synonymous exonic variants were sub-
sequently filtered by quality and minor-allele frequency (MAF)
reported in the 1000 Genomes project (2012 Feb release) (55) and
ESP6500 (56). Variants with MAF> 0.05 in either of the databases
were excluded. ANNOVAR (Version 2014-07-22) (57) was used
for annotations and prediction of functional consequences. The
presence of candidate deleterious variants was confirmed by
amplifying the regions of interest by PCR and subjecting those
to direct sequencing. The DNA oligonucleotide sequences used
are shown in Supplementary Material, Table S2.
Transmission electron microscopy
Transmission electron microscopy was performed on day 30
contracting EBs fixed with 2% glutaraldehyde in 0.1M cacodylate
buffer. Post fixation was performed at room temperature for 1 h
with 1% osmium and 1.5% potassium ferrocyanide. The samples
were dehydrated in graded acetone and embedded in epoxy
resin at 60 C. Half micron sections were stained with 1% tolui-
dine blue and ultra-thin section were cut on Leica EM UC7 ultra-
microtome and double stained with 1% uranyl acetate and lead
citrate. Ultrastructural examination was performed with Philips
CM 100 TEM at 100 kV. Digital images were recorded with an
AMT40 CCD camera (Deben, Bury St. Edmunds, Suffolk, UK).
Quantitative RT-PCR
Total RNA was isolated using ReliaPrepTM RNA Cell Miniprep
System (Promega, Madison, MI) at different points during the
differentiation process. 1mg of total RNA was used for reverse
transcription using the GoScriptTM Reverse Transcription
System (Promega). Quantitative RT-PCR was performed using a
Quant Studio 7 real-time PCR system with the GoTaq qPCR
Master Mix (Promega). Data were analysed using the compara-
tive threshold cycle (Ct) method. In all samples, the results were
normalised to the expression level of the housekeeping gene
GAPDH, and referenced to human embryonic heart cDNA (ob-
tained from Human Developmental Biology Resource, Carnegie
Stage 14). Primer sequences for qRT-PCR assays are shown in
Supplementary Material, Table S3.
Generation of iPSC-derived cardiomyocytes and
electrophysiological recordings
To facilitate electrophysiological recordings and RNA-seq analy-
sis described below, a monolayer based method was used for
generation of cardiomyocytes. In brief, iPSCs were passaged at a
density such that they reached confluence 3–4 days after pas-
saging. On day 0 of differentiation, mTeSR1 was replaced with
RPMI supplemented with 2% B27 without insulin (both from Life
Technologies). On day 1 this basal medium was supplemented
with CHIR99021 trihydrochloride (Tocris) at either 6, 9 or 12 mM
concentrations depending on the cell line and passage. On day 1
the medium was changed to base medium. On day 3 the me-
dium was changed to a mixture of fresh basal medium and the
existing medium from the culture in a 1:1 ratio, this was supple-
mented with 5mM IWP2 (Tocris). On day 5 the medium was
changed to base medium. On day 7 the medium was changed to
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maintenance medium consisting of RPMI supplemented with
2% B27. On day 9 the medium was changed to metabolic purifi-
cation medium consisting of RPMI without glucose supple-
mented with 2% B27. Purification medium was changed on days
11 and 13. On day 14 the medium was changed back to mainte-
nance medium. On day 15 the medium was changed to mainte-
nance medium supplemented with 10mM Y27632 and incubated
for 2 h in standard conditions. The cultures were then washed
with DPBS and incubated 0.25% trypsin/EDTA in standard con-
ditions for 5–20 min until the fragments detached from the cul-
ture surface. Fragments were gently triturated to produce
clusters of cells and equal volume of RPMI with 20% FBS added
to inactivate the trypsin. The cell suspension was centrifuged at
200g for 4 min at 20 C, the supernatant aspirated and the pellet
re-suspended in RPMI with 20% FBS supplemented with 10 mM
Y27632. The concentration of cells in suspension was estimated
using a haemocytometer and the cells were transferred to
matrigel coated culture-ware at a density of 0.125 – 0.25 106
cells per cm2 and incubated overnight in standard conditions.
The follow day the medium was changed to maintenance me-
dium which was changed every other day thereafter.
On day 25-30 of differentiation cultures were re-plated using
the same method of enzymatic dissociation into matrigel
coated wells of a 96 well glass bottomed plate (MatTek,
Ashland, MA) using the same technique. Between 40–80 103
cells were plated in each well depending on the cell line. A frac-
tion of the cells were used for the assessment of differentiation
and purification efficiency by flow cytometry. Cells were fixed
for 30 min in 4% formaldehyde at room temperature and then
permeabilised with 0.1% Triton X-100 for 15 min. Cells were
blocked by incubation with 10% FBS for 30 min. Aliquots of
1105 cells were incubated with antibodies to the proteins if in-
terest in a volume of 100ul, in the dark, at room temperature for
45 min. The antibodies used were: anti-cTnI-Alexa647 (1:20) (BD
Biosciences), and an isotype controls from the same manufac-
turer and matched for protein concentration. Samples were
washed once using a BD wash/lyse prior to analysis with an
LSRII (BD Biosciences) flow cytometer. Flow cytometry data was
analysed using FACS Diva software (BD). After the exclusion of
debris and doublets samples were excluded if<75% of single
cell events were classified as positive for the anti-cTnI label.
On day 30–40 the medium was replaced 2 lM Fura-4F in se-
rum free medium (SFM) and incubated for 30 min in standard
conditions. SFM consisted of DMEM without phenol red supple-
mented with 10mM galactose, 10mM sodium pyruvate and
2 mM L-glutamine (all from ThermoFisher Scientific). Cells were
washed with SFM and incubated for a further 30 min in SFM.
Calcium transients were recorded using the CellOPTIQVR plat-
form (Clyde Biosciences Ltd) (58). For each well of the plates, the
Fura-4F signal was recorded from a 0.2 mm 0.2 mm area using
a 40 (NA 0.6) objective lens. Ratiometric imaging was per-
formed using fast switching between light-emitting diode (LED)
excitation wavelengths of 355610 nm and 3806 10nm. Emitted
light was collected by a photomultiplier (PMT) at 510–560 nm.
The two fluorescence signals were digitized at 1kHz, and the
ratio of fluorescence (long wavelength/short wavelength) was
used to identify the occurrence of calcium transients.
Isoprenaline responses were determined by the addition of 1 mM
isoprenaline (Sigma). Beat rates before and 5 min after isoprena-
line application were determined by calculating the number of
calcium transients in a 30 s period. For each cell line, at least
3 independent differentiation experiments were tested and cells
from each differentiation experiment were plated into at least
3 wells of the 96 well plate. Control and disease lines were
tested simultaneously with repeated analysis on 2 different
dates. The mean beat rates and change in beat rates were calcu-
lated for cells from a given differentiation experiment and these
means used for inferential statistics comparing cell lines.
RNA-seq analysis (RNA-seq)
Total RNA was submitted to the Genomic Technologies Core
Facility (GTCF). Quality and integrity of the RNA samples were
assessed using a 2200 TapeStation (Agilent Technologies) and
then libraries generated using the TruSeqVR Stranded mRNA as-
say (Illumina, Inc.) according to the manufacturer’s protocol.
Briefly, total RNA (0.1-4ug) was used as input material from
which polyadenylated mRNA was purified using poly-T, oligo-
attached, magnetic beads. The mRNA was then fragmented
using divalent cations under elevated temperature and then re-
verse transcribed into first strand cDNA using random primers.
Second strand cDNA was then synthesised using DNA polymer-
ase I and RNase H. Following a single 0A0 base addition, adapters
were ligated to the cDNA fragments, and the products then pu-
rified and enriched by PCR to create the final cDNA library.
Adapter indices were used to multiplex libraries, which were
pooled prior to cluster generation using a cBot instrument. The
loaded flow-cell was then paired-end sequenced (76þ 76 cycles,
plus indices) on an Illumina HiSeq4000 instrument. Finally, the
output data was demultiplexed (allowing one mismatch) and
BCL-to-Fastq conversion performed using Illumina’s bcl2fastq
software, version 2.17.1.14. Reads from patient samples
(88,023,772) and control (113,283,210 reads) were analysed with
Kallisto (v0.43.0) (59) to quantify the abundances of transcripts
and genes within each sample. Reads were pseudo-aligned to
the human transcriptome GRCh38, release 79. Sleuth (60) (Wald
test) was then used to calculate differential expression of tran-
scripts using the Kallisto bootstrap estimates.
Supplementary Material
Supplementary Material is available at HMG online.
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